How much upside really exist in CenturyLink Inc. (CTL) and AbbVie Inc. (ABBV)?

You should consider shares of CenturyLink Inc. (NYSE:CTL) and AbbVie Inc. (NYSE:ABBV) if you are looking for a great stocks to invest in. Starting with the CTL shares, which traded at $13.06 at the close of the recent session, dropping -0.91%. On Wednesday, the company’s shares shed -$0.12 from its value which represented in intraday trading. The stock is now -1.14% lower in year-to-date (YTD) trading. CTL’s intraday high was $13.185 while its lowest price touched $13.03. The stock’s 52-week high price is $16.44, which means the current price is at -20.56%. In terms of trading activity, the daily trading volume fell to 8099458 against 200-day average trading volume of 12,201,221 shares.

What are analyst forecasts for CenturyLink Inc. (NYSE:CTL)?

At a consensus rating of 2.73, CTL is trending as a streaking Hold, as it has been the case a month ago when 15 analysts called it a Hold. Two months ago, 14 analysts recommended, on average, that CTL stock is a Hold. The Technology company’s shares’ overall bearish trend saw it close higher on Wednesday compared to its opening price of $13.15 on the day.

Forecasts for CenturyLink Inc. (NYSE:CTL) give the stock a fair value for the growth of 3.26% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $13.50, which means the price per share could rise by nearly $0.44. The price range target is between a low of $10.00 and a high of $16.00. The stock would need to gain by about $18.37 to hit the estimated high or 0.74% from its 12-month low.

The consensus among 16 analysts is that it is a good time for one to Hold in the CenturyLink Inc. 2 analysts rate CTL as a Buy, with 4 of 16 analysts rate it as a Sell. 0 have valued the stock as Overweight and 10 have recommended that investors Hold.

CenturyLink Inc. (NYSE:CTL) Upgrades and Downgrades

In terms of rating changes, Morgan Stanley on December 17, 2019, Downgrade CenturyLink Inc. (CTL) at Equal-Weight. Analysts at Evercore ISI have assigned a Underperform rating for the stock in their research note on December 11, 2019 with an estimated price target of $14. Moreover, Guggenheim analysts issued a rating of Sell for the stock on November 06, 2019, giving it a price target of $10 for the next 12 months. On August 08, 2019, the stock earned a Mkt Perform rating due to an analyst call from Raymond James, while analysts from JP Morgan on August 08, 2019 suggested that the stock is Underweight.

AbbVie Inc. (NYSE:ABBV) adds $1.06 on Wednesday

The ABBV stock has risen 0.81% year-to-date and is currently trading at $89.26, which is -2.97% below its 52-week high. The company shares gained 1.20% on the day and have risen nearly 42.45% off a low hit. At current levels, AbbVie Inc. has a valuation of about $32.87B. As of 01/15/20, this stock has fallen -0.29% during the week and closed at $88.20 in the previous session. However, recent AbbVie Inc. stock performance shows that ABBV shares are 1.62% up over the last month, and 19.81% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $1.94, with the trailing 12-month share earnings at $2.23. The ratio is expected to be up by 12.90% for the current year 2019 and 6.30% for next year. Over the next 5-year period, earnings per share will be 3.67%. But will the ABBV stock surprise in the current quarter results, where the $2.33 actual EPS reported on 9/29/2019 surprised by 1.30% or was higher by $0.03 from the estimated $2.3.

Sales Growth to climb 5.50% for the year

How well will AbbVie Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $8.61B and $8.84B in current quarter sales. The consensus estimated for the current quarter is $8.71B from sales. Forecasts for this fiscal year are between $33.17B and $33.42B and the consensus estimate for sales is at $33.3B. ABBV has its next quarter sales estimates at between $8.02B and $8.04B, with the quarter-over-quarter growth estimates at 2.60% and the annual growth forecast for the year at 5.50%.

Who owns shares in AbbVie Inc. (ABBV)?

Let’s briefly focus on the share ownership of the AbbVie Inc. (NYSE:ABBV) stock, where we find that 73.75% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 121.76 million shares or 8.23% of shares outstanding. Blackrock Inc. and Capital Research Global Investors held 101.64 million and 100.61 million representing 6.87% and 6.80% respectively at the close of the last trading session. As of Sep 29, 2019, State Street Corporation accounted for 68.78 million shares at over 5.21 billion. This represented 4.65% of shares outstanding. FMR, LLC held 37.31 million shares at over 2.83 billion representing 2.52% of shares outstanding.

ABBV Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at AbbVie Inc. (ABBV), a total of 15515 shares have been sold by insiders over the last 6 months while 217203 shares were added in the same time span. On 2/28/2019, Chairman & Chief Executive Officer by the name Gonzalez Richard A sold 72925.0 shares worth $5.8 million at the price of $79.41 per share. Filings also show that Chase William Joseph sold a total of 27276.0 shares on 2/28/2019 valued at $2.2 million. Since the last insider activity, the company’s share price has climbed 12.65%.